Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Quidel Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Quidel Corp ranked in the 59th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Quidel Corp ended up being:
The company's balance sheet shows it gets 99% of its capital from equity, and 1% of its capital from debt. Its equity weight surpasses that of 88.91% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 5.46% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.69% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as QDEL, try CBPO, PBH, UTHR, ANTM, and UHS.
What happened Shares of Quidel (NASDAQ: QDEL), which makes diagnostic healthcare products, popped 27.9% in June, according to data from S&P Global Market Intelligence. The S&P 500 returned 2% last month.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * Akero Therapeutics Inc (NASDAQ: AKRO) * Amgen, Inc. (NASDAQ: AMGN) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Champions Oncology Inc (NASDAQ: CSBR) * Crispr Therapeutics AG (NASDAQ: CRSP) * Cytokinetics, Inc. (NASDAQ: CYTK) * DexCom, Inc. (NASDAQ: DXCM) * Eli Lilly And Co (NYSE: LLY) * Fate Therapeutics Inc (NASDAQ: FATE) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Illumina, Inc. (NASDAQ: ILMN) * Immunomedics, Inc. (NASDAQ: IMMU) (announced positive late-stage...